Furthermore, recent evidence has shown that blocking immune checkpoints, such as inhibition of programmed cell death-1/programmed cell death ligand 1 (PD-1/D-L1), are effective in ccRCC (10–14). This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.